Crinetics To Present New Data Results Of The Phase 3 PATHFNDR-2 Trial Showing Increasing Evidence Positioning Once-Daily, Oral Paltusotine As Potential First-Choice Treatment Option for Acromegaly At ENDO 2024
Portfolio Pulse from Benzinga Newsdesk
Crinetics Pharmaceuticals presented new data from its Phase 3 PATHFNDR-2 trial at ENDO 2024, showing promising results for its oral, once-daily treatment for acromegaly, paltusotine. The data indicate rapid and sustained IGF-1 responses and fewer symptom exacerbations compared to standard care. Crinetics plans to complete the NDA submission for paltusotine in the second half of 2024.
June 03, 2024 | 4:02 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Crinetics Pharmaceuticals presented positive Phase 3 trial data for paltusotine, showing it as a potential first-choice treatment for acromegaly. The company plans to submit an NDA in the second half of 2024.
The positive Phase 3 trial results and the upcoming NDA submission are likely to boost investor confidence and positively impact CRNX's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100